Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms

The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it awakens and provokes a cli...

Source: Malaria Journal - January 22, 2018 Category: Infectious Diseases Authors: J. Kevin Baird, Katherine E. Battle and Rosalind E. Howes Tags: Commentary Source Type: research